Global healthcare leader Abbott has announced the launch of the HBsAg Next Qualitative solution in India to enhance detection of the hepatitis B virus (HBV). This assay will help improve patient outcomes while maintaining safe blood supplies. This highly sensitive chemiluminescent microparticle immunoassay (CMIA) assists in the early and enhanced detection of HBV in human serum and plasma (blood) samples and in population screening. A chemiluminescent immunoassay is a variation of the standard enzyme immunoassay, a biochemical technique used in immunology.
Early identification of HBV infections allows patients to receive the necessary care to prevent or delay progression of advanced liver diseases. Moreover, it also reduces the risk of transmission.
The HBsAg Next Qualitative assay is an advanced, next generation solution to better support the earlier detection of HBV. It detects HBV surface antigen (HBsAg) in human serum and plasma. Moreover, it overcomes traditional challenges by showcasing the highest level of assay performance required to detect infection in immunocompromised groups.
Dr. Jaganathan Sickan, senior associate director, medical affairs, Core Diagnostics at Abbott said,
